What Cannabis Rescheduling Means for State Laws
By
Navigating the Shift: What Cannabis Rescheduling Means for State Laws
In a landmark move, President Trump signed an executive order on December 18, 2025, directing the Department of Justice to expedite the rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act.
This change acknowledges cannabis's potential medical benefits and moderate risk of dependence, placing it alongside substances like ketamine and certain steroids. Federally, it opens doors for expanded research, eases tax burdens on businesses by eliminating IRS Section 280E restrictions, and could pave the way for FDA-approved pharmaceutical products.
However, it doesn't legalize recreational use or resolve conflicts between federal and state laws, cannabis remains tightly regulated. The real intrigue lies at the state level, where rescheduling could activate "trigger" provisions in existing laws or implicitly recognize medical use. Our accompanying map highlights these dynamics, focusing on key states.
Primary Trigger States: Texas, Illinois, and New Jersey
These states stand out as primary examples where federal rescheduling could directly influence local policies:
- Texas: With a limited low-THC medical program already in place, rescheduling might trigger broader access or regulatory reviews, potentially expanding beyond current restrictions.
- Illinois: As a state with full recreational legalization, the shift could align state scheduling with federal changes, unlocking tax deductions for operators and streamlining operations.
- New Jersey: Similarly recreational-legal, rescheduling may enhance business viability through federal tax relief and research opportunities, though it won't alter core state frameworks.
In these areas, the move could catalyze economic boosts for the industry without requiring new legislation.
States with Implicit Medical Recognition: Pharmaceutical-Only Pathways
Beyond the primaries, several states lack traditional dispensary systems but could see federal rescheduling technically endorse cannabis for medical purposes, strictly through pharmaceutical channels, like FDA-approved prescriptions via pharmacies. No over-the-counter or state-run dispensaries would emerge; access would mirror other Schedule III drugs. Highlighted on the map above:
- North Carolina, South Carolina, Tennessee, Kansas, Wisconsin: These have no or minimal medical programs, so rescheduling introduces federal medical acknowledgment without state infrastructure.
- Iowa (very limited medical program): Existing restrictions on THC levels might evolve, but remain pharmacy-bound.
- Georgia (low-THC only): Could build on its CBD-focused system for broader pharmaceutical options.
- Indiana: Similar to Georgia, with potential for low-THC medical expansion under federal guidelines.
This pharmaceutical-only model emphasizes controlled, prescription-based access, potentially benefiting patients in conservative states while avoiding broader legalization debates.
Overall, while Schedule III rescheduling is a step forward for medical recognition and industry relief, it stops short of full reform. States retain autonomy, and true harmonization may require congressional action. Check the map for a visual breakdown, and stay tuned as regulations unfold. 2026 could bring more clarity to this evolving landscape.
|
— For Institutional Investor Use Only. Not for Public Distribution —
Before investing you should carefully consider the Fund’s investment objectives, risks, charges and expenses. This and other information is in the prospectus and summary prospectus, a copy of which may be obtained by visiting the Fund’s website at www.AdvisorShares.com. Please read the prospectus carefully before you invest. Foreside Fund Services, LLC, distributor.
The Fund is subject to a number of risks that may affect the value of its shares. This section provides additional information about the Fund’s principal risks. The degree to which a risk applies to the Fund varies according to its investment allocation. Each investor should review the complete description of the principal risks before investing in the Fund. As with investing in other securities whose prices increase and decrease in market value, you may lose money by investing in the Fund. Cannabis-Related Company Risk – Cannabis-related companies are subject to various laws and regulations that may differ at the state/local and federal level. These laws and regulations may (i) significantly affect a cannabis-related company’s ability to secure financing, (ii) impact the market for marijuana industry sales and services, and (iii) set limitations on marijuana use, production, transportation, and storage. Cannabis-related companies may also be required to secure permits and authorizations from government agencies to cultivate or research marijuana. In addition, cannabis-related companies are subject to the risks associated with the greater agricultural industry, including changes to or trends that affect commodity prices, labor costs, weather conditions, and laws and regulations related to environmental protection, health and safety. Cannabis-related companies may also be subject to risks associated with the biotechnology and pharmaceutical industries. These risks include increased government regulation, the use and enforcement of intellectual property rights and patents, technological change and obsolescence, product liability lawsuits, and the risk that research and development may not necessarily lead to commercially successful products. Shares are bought and sold at market price not net asset value (NAV) and are not individually redeemed from the Fund. Market price returns are based on the midpoint of the bid/ask spread at 4:00 pm Eastern Time (when NAV is normally determined) and do not represent the return you would receive if you traded at other times. AIL-854359-2025-12-16 |